72 studies found for:    cladribine
Show Display Options
Rank Status Study
1 Recruiting Allogeneic Transplantation Using Timed Sequential Busulfan, Cladribine, and Fludarabine Conditioning in Patients With Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Conditions: Acute Myeloid Leukemia;   Myelodysplastic Syndrome
Interventions: Drug: Busulfan;   Drug: Fludarabine;   Drug: Cladribine;   Procedure: Stem Cell Transplant;   Drug: G-CSF;   Drug: Methotrexate
2 Recruiting Cladribine Plus Idarubicin Plus Cytarabine (ARAC) in Patients With Acute Myeloid Leukemia (AML), High Risk Myelodysplastic Syndrome (HR MDS) or Myeloid Blast Phase of Chronic Myeloid Leukemia (CML)
Condition: Leukemia
Interventions: Drug: Cladribine;   Drug: Cytarabine;   Drug: Idarubicin;   Behavioral: Phone Calls
3 Completed
Has Results
Drug-Drug Interaction of Cladribine and Pantoprazole in Multiple Sclerosis Subjects
Condition: Multiple Sclerosis
Interventions: Drug: Cladribine;   Drug: Pantoprazole
4 Recruiting Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Condition: Leukemia
Interventions: Drug: Cladribine;   Drug: Cytarabine;   Drug: Decitabine
5 Recruiting 2CDA With Rituximab in Hairy Cell Leukemia
Condition: Leukemia
Interventions: Drug: Cladribine;   Drug: Rituximab
6 Recruiting Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
Conditions: Acute Biphenotypic Leukemia;   de Novo Myelodysplastic Syndrome;   Previously Treated Myelodysplastic Syndrome;   Recurrent Adult Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndrome;   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: Cladribine;   Drug: Cytarabine;   Biological: Filgrastim;   Other: Laboratory Biomarker Analysis;   Drug: Mitoxantrone Hydrochloride
7 Recruiting Prospective Observational Long-term Safety Registry of Multiple Sclerosis Patients Who Have Participated in Cladribine Clinical Trials
Condition: Multiple Sclerosis
Intervention: Drug: Cladribine
8 Recruiting Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia
Condition: Hairy Cell Leukemia
Interventions: Drug: Cladribine;   Drug: Rituximab
9 Completed
Has Results
Oral Cladribine in Early Multiple Sclerosis (MS)
Condition: Multiple Sclerosis
Interventions: Drug: Cladribine;   Drug: Placebo;   Drug: Rebif® new formulation (RNF)
10 Completed 2-Chlorodeoxyadenosine and Cytarabine in Patients With Idiopathic Hypereosinophilic Syndrome (HES)
Condition: Leukemia
Interventions: Drug: 2-CdA;   Drug: Ara-C;   Drug: G-CSF (Granulocyte colony-stimulating factor)
11 Recruiting Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011)
Condition: Mantle Cell Lymphoma
Interventions: Drug: Rituximab;   Drug: bortezomib;   Drug: Cladribine
12 Active, not recruiting Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma
Conditions: Lymphoma;   Mantle Cell Lymphoma;   Indolent Lymphoma;   SLL
Interventions: Drug: rituximab;   Drug: bortezomib;   Drug: cladribine
13 Recruiting 4-Arm Phase II Study of SGI-110 in Elderly Acute Myeloid Leukemia (AML)
Condition: Leukemia
Interventions: Drug: SGI-110;   Drug: Idarubicin;   Drug: Cladribine
14 Active, not recruiting Treatment of Macroglobulinemic Lymphoma With 2CdA, Cyclophosphamide and Rituximab
Condition: Lymphoma
Interventions: Drug: 2CdA;   Drug: Cyclophosphamide;   Drug: Rituximab
15 Active, not recruiting Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma
Conditions: Recurrent B-Cell Non-Hodgkin Lymphoma;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Indolent Adult Non-Hodgkin Lymphoma;   Refractory B-Cell Non-Hodgkin Lymphoma
Interventions: Drug: Cladribine;   Other: Laboratory Biomarker Analysis;   Biological: Rituximab;   Drug: Vorinostat
16 Recruiting Therapy Optimisation for the Treatment of Hairy Cell Leukemia
Condition: Hairy Cell Leukemia
Intervention: Drug: Cladribine s.c. injection, HCL treatment
17 Completed
Has Results
A Safety and Efficacy Study of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: Cladribine 5.25 mg/kg;   Drug: Cladribine 3.5 mg/kg;   Other: Placebo
18 Terminated R-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma
Conditions: Chronic Lymphocytic Leukaemia;   Small Lymphocytic Lymphoma
Interventions: Drug: Rituximab;   Drug: Cladribine
19 Completed Cladribine Based Induction Therapy With All-Trans Retinoic Acid and Midostaurin in Relapsed/Refractory AML
Condition: Leukemia, Myeloid, Acute
Interventions: Drug: Granulocyte colony-stimulating factor (G-CSF);   Drug: Cladribine;   Drug: Cytarabine;   Drug: All-Trans Retinoic Acid (ATRA);   Drug: Midostaurin
20 Not yet recruiting Filgrastim, Cladribine, Cytarabine and Mitoxantrone With or Without Sorafenib Tosylate in Treating Patients With Newly-Diagnosed, High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome
Conditions: Acute Biphenotypic Leukemia;   Acute Myeloid Leukemia;   de Novo Myelodysplastic Syndrome;   Myeloproliferative Neoplasm
Interventions: Drug: Cladribine;   Drug: Cytarabine;   Biological: Filgrastim;   Other: Laboratory Biomarker Analysis;   Drug: Mitoxantrone Hydrochloride;   Other: Quality-of-Life Assessment;   Drug: Sorafenib Tosylate

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years